Asset Details
Do you wish to reserve the book?
Case report: Satralizumab therapy for bilateral refractory optic neuritis following the first dose of bivalent human papilloma virus vaccine
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Case report: Satralizumab therapy for bilateral refractory optic neuritis following the first dose of bivalent human papilloma virus vaccine
Do you wish to request the book?
Case report: Satralizumab therapy for bilateral refractory optic neuritis following the first dose of bivalent human papilloma virus vaccine
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Case report: Satralizumab therapy for bilateral refractory optic neuritis following the first dose of bivalent human papilloma virus vaccine
2024
Overview
Demyelinating optic neuritis (DON) is a rare but sight-threatening ophthalmic condition which occasionally occurs after human papilloma virus (HPV) vaccination. We herein report a case of previously healthy 13-year-old girl who developed a bilateral refractory DON three days after the first dose of bivalent HPV vaccine. The patient experienced bilateral severe visual loss three days after HPV vaccination, and her vision was quickly deteriorated to no light perception one day after the onset of DON. Ophthalmic examination revealed sluggish pupillary light reflex and swollen optic disc in both eyes, and an emergent orbital MRI examination revealed bilateral hyperintensity and enlargement of the intraorbital optic nerve with contrast enhancement. Serological tests for aquaporin-4 IgG antibody, myelin oligodendrocyte glycoprotein IgG antibody, and other common autoantibodies were all negative. The patient showed poor response to 10 days of intravenous methylprednisolone pulse therapy (500 mg, 250 mg, and 125 mg twice per day for 4, 4, and 2 days, respectively). Hence, three-dosed subcutaneous satralizumab was used in the acute stage of DON as an adjunct therapy. Her vision gradually improved after satralizumab therapy, and increased to 20/20 and 20/32 in the right and left eye at the 3-month follow-up. To the best of our knowledge, this is the first case report of satralizumab therapy in the AQP-4 Ab and MOG-Ab dual seronegative isolated DON. Our study indicates that satralizumab may be a safe and efficient adjunct therapy which can be used in the acute stage of the refractory DON poorly responding to steroid pulse therapy.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Female
/ Humans
/ Lesions
/ Light
/ Myelin
/ Neuritis
/ Oligodendrocyte-myelin glycoprotein
/ Optic Neuritis - drug therapy
/ Papillomavirus Infections - immunology
/ Papillomavirus Vaccines - administration & dosage
/ Papillomavirus Vaccines - adverse effects
/ Serology
/ Steroids
/ Vaccines
/ Viruses
/ Vision
